Alzamend Neuro
ALZN
13 hedge funds and large institutions have $447K invested in Alzamend Neuro in 2025 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 0 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
27% more capital invested
Capital invested by funds: $351K → $447K (+$95.8K)
18% more funds holding
Funds holding: 11 → 13 (+2)
1.76% more ownership
Funds ownership: 4.7% → 6.46% (+1.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$56.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$51K |
| 3 |
Morgan Stanley
New York
|
+$40.8K |
| 4 |
VF
Virtu Financial
New York
|
+$28.5K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$28.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DS
1
DRW Securities
Chicago,
Illinois
| $212K | +$56.9K | +25,074 | +27% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $50.1K | +$15.7K | +6,928 | +34% |
|
|
3
UBS Group
Zurich,
Switzerland
| $44.7K | +$51K | +22,492 | +1,084% |
|
4
Vanguard Group
Malvern,
Pennsylvania
| $39.3K | – | – | – |
|
|
5
Morgan Stanley
New York
| $32.8K | +$40.8K | +18,000 | New |
|
|
VF
6
Virtu Financial
New York
| $23K | +$28.5K | +12,582 | New |
|
|
XT
7
XTX Topco
George Town,
Cayman Islands
| $22.7K | +$28.3K | +12,470 | New |
|
|
CA
8
Clearstead Advisors
Cleveland,
Ohio
| $18.2K | – | – | – |
|
|
TRCT
9
Tower Research Capital (TRC)
New York
| $3.79K | +$1.08K | +475 | +30% |
|
10
BlackRock
New York
| $795 | – | – | – |
|
11
Bank of America
Charlotte,
North Carolina
| $78 | +$14 | +6 | +16% |
|
|
SS
12
SBI Securities
Tokyo,
Japan
| $40 | – | – | – |
|
|
HIA
13
Harbor Investment Advisory
Lutherville,
Maryland
| $2 | – | – | – |
|
|
14
Citigroup
New York
| – | -$2 | -1 | Closed |
|
ALZN Hedge Fund Activity: Q4 2025 in Review
13 of the 8,238 institutional investors tracked by Wall St. Rank reported a position in Alzamend Neuro (ALZN) for Q4 2025, worth a combined $447K — up 27% from $351K a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new ALZN positions and 1 closed out — a net gain of 2 holders — while 5 added to existing stakes and 0 trimmed.
The largest buyer was DRW Securities, adding an estimated $56.9K. The largest seller was Citigroup, exiting entirely with an estimated $2 sold.
- 13 institutional investors held Alzamend Neuro (ALZN) as of Q4 2025, up from 11 in Q3 2025.
- Funds reported $447K of Alzamend Neuro stock for Q4 2025, up 27% quarter-over-quarter.
- 3 funds opened new Alzamend Neuro positions in Q4 2025 and 1 closed out, a net change of +2 holders.
- The largest Alzamend Neuro buyer in Q4 2025 was DRW Securities, an estimated $56.9K added.
- The largest Alzamend Neuro seller in Q4 2025 was Citigroup, an estimated $2 sold.
Based on aggregated 13F filings for Q4 2025.